There is no confirmed end date for the Concerta shortage. As of 2025, multiple manufacturers of methylphenidate extended-release products (the active ingredient in Concerta) are reporting supply disruptions for different reasons, and the timeline for full resolution remains unclear. The brand-name Concerta made by Janssen is currently listed as available, but several generic versions remain on shortage, making it difficult for many patients to fill prescriptions at their usual pharmacy and price.
Why the Shortage Is Happening
The Concerta shortage has no single cause. Different manufacturers cite different problems. Teva, one of the largest generic suppliers, points to manufacturing delays. Mallinckrodt reports a shortage of the active ingredient itself. Trigen and Vertical both say the issue is increased demand outpacing their production capacity. Sandoz is still shipping product but has started allocating supply to prevent a gap, which means pharmacies may receive less than they order.
On the demand side, ADHD medication prescribing has surged. A large population study published in JAMA Network Open found that new stimulant prescriptions increased by 157% between 2015 and 2023. The pace accelerated sharply after 2020, jumping roughly 29% per year compared to about 7% per year before the pandemic. Researchers point to several possible drivers: greater awareness of ADHD in adults, increased screen time and remote work, and broader access to telehealth making it easier to get diagnosed and treated. That wave of new prescriptions has put sustained pressure on a supply chain that was already stretched thin.
What the DEA Is Doing About Production Limits
One often-overlooked factor in ADHD medication shortages is that the DEA sets annual caps on how much of each controlled substance can be manufactured in the United States. In October 2025, the DEA proposed raising the production quota for methylphenidate from about 53.3 million grams to 58.3 million grams, an increase of roughly 9%. The agency cited domestic shortages reported by multiple manufacturers and specifically noted that “shortage of an active ingredient” was a recurring reason on the FDA’s drug shortage list.
The quota increase is meant to give manufacturers room to produce more and to support development of new manufacturing processes for the active ingredient. This is a necessary step, but raising a production cap doesn’t instantly translate into pills on pharmacy shelves. Manufacturers still need to source raw materials, scale up production, and move product through distribution. It typically takes months for quota adjustments to meaningfully improve supply at the pharmacy level.
Brand-Name vs. Generic Availability
If you’ve been told Concerta is “available” but still can’t find your medication, the distinction between brand-name and generic matters here. Janssen, which makes brand-name Concerta, currently reports its product is available. But brand-name Concerta is significantly more expensive, and not every insurance plan covers it when a generic exists on paper.
The generic landscape is more complicated than most patients realize. The FDA downgraded the therapeutic equivalence ratings for the Mallinckrodt and Kudco generics years ago, meaning pharmacists can no longer automatically substitute them for Concerta. They’re still approved, but they aren’t considered interchangeable. An authorized generic made under a licensing agreement with Janssen (marketed by Actavis) is bioequivalent and fully substitutable. Mylan also has an approved generic. So when you’re searching for “generic Concerta,” you may encounter products that differ in how well they match the original, which is worth discussing with your prescriber if you notice a change in how your medication works after switching.
What You Can Do Right Now
Waiting for an official “shortage over” announcement is not a practical strategy. The supply situation has been fluctuating for months, and availability varies by pharmacy, region, and dosage strength. There are concrete steps that can help.
Call multiple pharmacies. Stock levels vary widely even within the same city. Independent pharmacies sometimes have better luck sourcing from smaller distributors. If your pharmacy is the only option in your area or the only one your insurance covers, ask whether they accept manufacturer coupons or discount programs that might open up alternatives.
Contact your prescriber early. Don’t wait until you’re out of medication. If your usual formulation is unavailable, your doctor can discuss switching to a different methylphenidate product or adjusting your prescription in a way that matches what’s actually in stock. Some patients have had success with partial fills, where the pharmacy dispenses what they have on hand and fills the rest when new stock arrives.
Consider the broader treatment picture. Cognitive behavioral therapy is an evidence-based treatment for ADHD that works alongside medication, and it becomes especially valuable during supply disruptions. Practical strategies like time management tools, structured routines, and environmental changes can help bridge gaps. These aren’t replacements for medication, but they can reduce the impact of missed doses while you work through the shortage.
Realistic Outlook
The honest answer is that no manufacturer or regulatory agency has committed to a specific date when methylphenidate supply will fully normalize. The DEA’s quota increase is a positive signal, and Janssen’s continued availability of brand-name Concerta provides a safety net for some patients. But the underlying demand trend, with prescriptions still climbing year over year, means that even when production catches up, the margin between supply and demand will likely remain tight for the foreseeable future.
The best way to stay informed is to check the ASHP drug shortage database, which tracks manufacturer-by-manufacturer updates in close to real time. Your pharmacist can also check wholesale availability for your specific dosage strength, which often gives a more accurate picture than national-level reports.